The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Osteonecrosis of the Jaw in Cancer After Treatment With Bisphosphonates: Incidence and Risk Factors
Abstract
Purpose: Osteonecrosis of the jaw (ONJ) has been associated recently with the use of pamidronate and zoledronic acid. We studied the incidence, characteristics, and risk factors for the development of ONJ among patients treated with bisphosphonates for bone metastases. Patients and Methods: ONJ was assessed prospectively since July 2003. The first bisphosphonate treatment among patients with ONJ was administered in 1997. Two hundred fifty-two patients who received bisphosphonates since January 1997 were included in this analysis. Results: Seventeen patients (6.7%) developed ONJ: 11 of 111 (9.9%) with multiple myeloma, two of 70 (2.9%) with breast cancer, three of 46 (6.5%) with prostate cancer, and one of 25 (4%) with other neoplasms (P = .289). The median number of treatment cycles and time of exposure to bisphosphonates were 35 infusions and 39.3 months for patients with ONJ compared with 15 infusions (P < .001) and 19 months (P = .001), respectively, for patients with no ONJ. The incidence of ONJ increased with time to exposure from 1.5% among patients treated for 4 to 12 months to 7.7% for treatment of 37 to 48 months. The cumulative hazard was significantly higher with zoledronic acid compared with pamidronate alone or pamidronate and zoledronic acid sequentially (P < .001). All but two patients with ONJ had a history of dental procedures within the last year or use of dentures. Conclusion: The use of bisphosphonates seems to be associated with the development of ONJ. Length of exposure seems to be the most important risk factor for this complication. The type of bisphosphonate may play a role and previous dental procedures may be a precipitating factor.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Marx, R. E. (2003) · Journal of Oral and Maxillofacial Surgery · doi:10.1016/s0278-2391(03)00720-1 · Cited by 3,036
Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases
Ruggiero, S. L., Mehrotra, B., Rosenberg, T. J., & Engroff, S. L. (2004) · Journal of Oral and Maxillofacial Surgery · doi:10.1016/j.joms.2004.02.004 · Cited by 2,057
Efficacy of Pamidronate in Reducing Skeletal Events in Patients with Advanced Multiple Myeloma
Berenson, J. R., Lichtenstein, A., Porter, L., Dimopoulos, M. A., Bordoni, R., George, S., Lipton, A., Keller, A., Ballester, O., Kovacs, M. J., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199602223340802 · Cited by 1,081
Self-citationCellular and molecular mechanisms of action of bisphosphonates
Rogers, M. J., Gordon, S., Benford, H. L., Coxon, F. P., Luckman, S. P., Monkkonen, J., & Frith, J. C. (2000) · Cancer · doi:10.1002/1097-0142(20000615)88:12+<2961::aid-cncr12>3.0.co;2-l · Cited by 977
Hypercalcemia Associated with Cancer
Stewart, A. F. (2005) · New England Journal of Medicine · doi:10.1056/nejmcp042806 · Cited by 973
Hillner, B. E., Ingle, J. N., Chlebowski, R. T., Gralow, J., Yee, G. C., Janjan, N. A., Cauley, J. A., Blumenstein, B. A., Albain, K. S., Lipton, A., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.08.017 · Cited by 970
Bisphosphonates: A review of their pharmacokinetic properties
Lin, J. H. (1996) · Bone · doi:10.1016/8756-3282(95)00445-9 · Cited by 932
Rosen, L. S., Gordon, D., Kaminski, M., Howell, A., Belch, A. R., Mackey, J. R., Apffelstaedt, J., Hussein, M., Coleman, R. E., Reitsma, D. J., et al. (2001) · PubMed · Cited by 896
Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid.
Wood, J., Bonjean, K., Ruetz, S., Bellahcène, A., Devy, L., Foidart, J. M., Castronovo, V., & Green, J. R. (2002) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.035295 · Cited by 854
Bisphosphonates: from the laboratory to the clinic and back again
Russell, R. G. G., & Rogers, M. J. (1999) · Bone · doi:10.1016/s8756-3282(99)00116-7 · Cited by 840
Cited by
Ruggiero, S. L., Dodson, T. B., Fantasia, J., Goodday, R., Aghaloo, T., Mehrotra, B., & O'Ryan, F. (2014) · Journal of Oral and Maxillofacial Surgery · doi:10.1016/j.joms.2014.04.031 · Cited by 2,905
Khosla, S., Burr, D., Cauley, J., Dempster, D. W., Ebeling, P. R., Felsenberg, D., Gagel, R. F., Gilsanz, V., Guise, T., Koka, S., et al. (2007) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.0707onj · Cited by 1,650
“However, for those who received zoledronic acid alone, the hazard was 1% within the first year but rose to 21% at 3 yr.((18))”
BackgroundBisphosphonates: Mechanism of action and role in clinical practice
Drake, M. T., Clarke, B. L., & Khosla, S. (2008) · Mayo Clinic Proceedings · doi:10.4065/83.9.1032 · Cited by 1,644
Khan, A. A., Morrison, A., Hanley, D. A., Felsenberg, D., McCauley, L. K., O'Ryan, F., Reid, I. R., Ruggiero, S. L., Taguchi, A., Tetradis, S., et al. (2015) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.2405 · Cited by 1,353
Ruggiero, S. L., Dodson, T. B., Assael, L. A., Landesberg, R., Marx, R. E., & Mehrotra, B. (2009) · Journal of Oral and Maxillofacial Surgery · doi:10.1016/j.joms.2009.01.009 · Cited by 1,328
Systematic Review: Bisphosphonates and Osteonecrosis of the Jaws
Woo, S.-B., Hellstein, J. W., & Kalmar, J. R. (2006) · Annals of Internal Medicine · doi:10.7326/0003-4819-144-10-200605160-00009 · Cited by 1,252
Ruggiero, S. L., Dodson, T. B., Aghaloo, T., Carlson, E. R., Ward, B. B., & Kademani, D. (2022) · Journal of Oral and Maxillofacial Surgery · doi:10.1016/j.joms.2022.02.008 · Cited by 1,141
(2007) · Journal of Oral and Maxillofacial Surgery · doi:10.1016/j.joms.2006.11.003 · Cited by 837
Nature and Frequency of Bisphosphonate-Associated Osteonecrosis of the Jaws in Australia
Mavrokokki, T., Cheng, A., Stein, B., & Goss, A. (2007) · Journal of Oral and Maxillofacial Surgery · doi:10.1016/j.joms.2006.10.061 · Cited by 650
Hoff, A. O., Toth, B. B., Altundag, K., Johnson, M. M., Warneke, C. L., Hu, M., Nooka, A., Sayegh, G., Guarneri, V., Desrouleaux, K., et al. (2008) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.080205 · Cited by 633
Ruggiero, S. L., Dodson, T. B., Assael, L. A., Landesberg, R., Marx, R. E., & Mehrotra, B. (2009) · Australian Endodontic Journal · doi:10.1111/j.1747-4477.2009.00213.x · Cited by 505
The Pathogenesis of Bisphosphonate-Related Osteonecrosis of the Jaw: So Many Hypotheses, So Few Data
Allen, M. R., & Burr, D. B. (2009) · Journal of Oral and Maxillofacial Surgery · doi:10.1016/j.joms.2009.01.007 · Cited by 451
Dimopoulos, M. A., Kastritis, E., Bamia, C., Melakopoulos, I., Gika, D., Roussou, M., Migkou, M., Eleftherakis-Papaiakovou, E., Christoulas, D., Terpos, E., et al. (2009) · Annals of Oncology · doi:10.1093/annonc/mdn554 · Cited by 437
Self-citationMedication-Related Osteonecrosis of the Jaw: MASCC/ISOO/ASCO Clinical Practice Guideline
Yarom, N., Shapiro, C. L., Peterson, D. E., Van Poznak, C. H., Bohlke, K., Ruggiero, S. L., Migliorati, C. A., Khan, A., Morrison, A., Anderson, H., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.01186 · Cited by 420
Kyle, R. A., Yee, G. C., Somerfield, M. R., Flynn, P. J., Halabi, S., Jagannath, S., Orlowski, R. Z., Roodman, D. G., Twilde, P., & Anderson, K. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.1269 · Cited by 409
Ripamonti, C. I., Maniezzo, M., Campa, T., Fagnoni, E., Brunelli, C., Saibene, G., Bareggi, C., Ascani, L., & Cislaghi, E. (2009) · Annals of Oncology · doi:10.1093/annonc/mdn526 · Cited by 405
Himelstein, A. L., Foster, J. C., Khatcheressian, J. L., Roberts, J. D., Seisler, D. K., Novotny, P. J., Qin, R., Go, R. S., Grubbs, S. S., O’Connor, T., et al. (2017) · JAMA · doi:10.1001/jama.2016.19425 · Cited by 356
Hellstein, J. W., Adler, R. A., Edwards, B., Jacobsen, P. L., Kalmar, J. R., Koka, S., Migliorati, C. A., & Ristic, H. (2011) · The Journal of the American Dental Association · doi:10.14219/jada.archive.2011.0108 · Cited by 363
Fliefel, R., Tröltzsch, M., Kühnisch, J., Ehrenfeld, M., & Otto, S. (2015) · International Journal of Oral and Maxillofacial Surgery · doi:10.1016/j.ijom.2015.01.026 · Cited by 363
Bisphosphonate-associated osteonecrosis: a long-term complication of bisphosphonate treatment
Migliorati, C. A., Siegel, M. A., & Elting, L. S. (2006) · The Lancet Oncology · doi:10.1016/s1470-2045(06)70726-4 · Cited by 342
Michaelson, M. D., Kaufman, D. S., Lee, H., McGovern, F. J., Kantoff, P. W., Fallon, M. A., Finkelstein, J. S., & Smith, M. R. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.3361 · Cited by 330
Bisphosphonate-associated adverse events
Papapetrou, P. D. (2009) · Hormones · doi:10.14310/horm.2002.1226 · Cited by 312
Pazianas, M., Miller, P., Blumentals, W. A., Bernal, M., & Kothawala, P. (2007) · Clinical Therapeutics · doi:10.1016/j.clinthera.2007.08.008 · Cited by 298
Zervas, K., Verrou, E., Teleioudis, Z., Vahtsevanos, K., Banti, A., Mihou, D., Krikelis, D., & Terpos, E. (2006) · British Journal of Haematology · doi:10.1111/j.1365-2141.2006.06230.x · Cited by 297
Self-citationBisphosphonate Associated Osteonecrosis of the Jaw
KHAN, A. A., SÁNDOR, G. K. B., DORE, E., MORRISON, A. D., ALSAHLI, M., AMIN, F., PETERS, E., HANLEY, D. A., CHAUDRY, S. R., LENTLE, B., et al. (2009) · The Journal of Rheumatology · doi:10.3899/jrheum.080759 · Cited by 280
Boonyapakorn, T., Schirmer, I., Reichart, P. A., Sturm, I., & Massenkeil, G. (2008) · Oral Oncology · doi:10.1016/j.oraloncology.2007.11.012 · Cited by 280
Osteonecrosis of the Jaw in a Patient on Denosumab
Aghaloo, T. L., Felsenfeld, A. L., & Tetradis, S. (2010) · Journal of Oral and Maxillofacial Surgery · doi:10.1016/j.joms.2009.10.010 · Cited by 275
Yoneda, T., Hagino, H., Sugimoto, T., Ohta, H., Takahashi, S., Soen, S., Taguchi, A., Toyosawa, S., Nagata, T., & Urade, M. (2010) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-010-0162-7 · Cited by 272
Castration-resistant Prostate Cancer: From New Pathophysiology to New Treatment Targets
Chi, K. N., Bjartell, A., Dearnaley, D., Saad, F., Schröder, F. H., Sternberg, C., Tombal, B., & Visakorpi, T. (2009) · European Urology · doi:10.1016/j.eururo.2009.06.027 · Cited by 253
Otto, S., Schreyer, C., Hafner, S., Mast, G., Ehrenfeld, M., Stürzenbaum, S., & Pautke, C. (2012) · Journal of Cranio-Maxillofacial Surgery · doi:10.1016/j.jcms.2011.05.003 · Cited by 252
Metadata
- Authors
- Bamias, A., Kastritis, E., Bamia, C., Moulopoulos, L. A., Melakopoulos, I., Bozas, G., Koutsoukou, V., Gika, D., Anagnostopoulos, A., Papadimitriou, C., Terpos, E., & Dimopoulos, M. A.
- Venue
- Journal of Clinical Oncology
- Published
- 2005-12-01
- Volume
- 23
- Issue
- 34
- Pages
- 8580-8587
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2137302084
- Cited by
- 1,149
- References
- 29
- FWCI
- 39.57
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.